Table 5.
Sensitivity analyses results
| Analysis | Cost, GBP | Quality-adjusted life expectancy, QALYs | ICER, GBP per QALY gained | ||||
|---|---|---|---|---|---|---|---|
| rt-CGM | SMBG | Difference | rt-CGM | SMBG | Difference | ||
| Base case | 79,866 | 77,172 | +2694 | 7.897 | 7.166 | +0.731 | 3684 |
| Dexcom rt-CGM GBP 1600 | 83,979 | 77,172 | 6807 | 7.897 | 7.166 | 0.731 | 9308 |
| Dexcom rt-CGM GBP 900 | 75,753 | 77.172 | –1419 | 7.897 | 7.166 | 0.731 | Dominant |
| Dexcom rt-CGM cost + 20% (GBP 1500) | 82,804 | 77,172 | 5532 | 7.897 | 7.166 | 0.731 | 7701 |
| Dexcom rt-CGM cost + 30% (GBP 1625) | 82,273 | 77,172 | 7101 | 7.897 | 7.166 | 0.731 | 9709 |
| Dexcom rt-CGM cost –20% (GBP 1000 | 76,928 | 77,172 | –244 | 7.897 | 7.166 | 0.731 | Dominant |
| Dexcom rt-CGM cost -30% (875) | 75,459 | 77,172 | –1713 | 7.897 | 7.166 | 0.731 | Dominant |
| rt-CGM utility benefit 0% | 79,866 | 77,172 | +2694 | 7.544 | 7.166 | +0.379 | 7112 |
| rt-CGM utility benefit –50% | 79,866 | 77,172 | +2694 | 7.721 | 7.166 | +0.555 | 4853 |
| rt-CGM utility benefit + 50% | 79,866 | 77,172 | +2694 | 8.073 | 7.166 | +0.907 | 2968 |
| rt-CGM utility benefit + FoH | 79,866 | 77,172 | +2694 | 8.195 | 7.166 | +1.029 | 2617 |
| rt-CGM HbA1c –30% | 81,643 | 77,172 | +4471 | 7.836 | 7.166 | +0.670 | 6671 |
| rt-CGM HbA1c +30% | 78,039 | 77,172 | +867 | 7.953 | 7.166 | +0.787 | 1102 |
| One SMBG/day | 79,866 | 73,760 | +6106 | 7.897 | 7.166 | +0.731 | 8349 |
| Two SMBG/day | 79,866 | 74,978 | +4888 | 7.897 | 7.166 | +0.731 | 6683 |
| Three SMBG/day | 79,866 | 76,197 | +3669 | 7.897 | 7.166 | +0.731 | 5017 |
| Four SMBG/day | 79,866 | 77,416 | +2450 | 7.897 | 7.166 | +0.731 | 3350 |
| Time horizon 10 years | 34,581 | 31,093 | +3488 | 4.988 | 4.610 | +0.378 | 9232 |
| Time horizon 15 years | 49,682 | 46,254 | +3428 | 6.315 | 5.801 | +0.514 | 6672 |
| Time horizon 20 years | 62,337 | 59,379 | +2958 | 7.136 | 6.519 | + 0.617 | 4794 |
| Baseline mean age 30 years, lifetime horizon | 280,648 | 291,986 | –11,338 | 13.711 | 12.537 | +1.174 | Dominant |
| Baseline mean age 40 years, lifetime horizon | 204,341 | 210,215 | –5874 | 12.180 | 11.096 | +1.084 | Dominant |
| Baseline mean age 50 years, lifetime horizon | 141,036 | 142,751 | –1715 | 10.442 | 9.489 | +0.953 | Dominant |
| Discount rate 1.5% | 104,459 | 101,859 | +2600 | 9.588 | 8.662 | +0.926 | 2808 |
| NG28 UK ethnic distribution | 75,309 | 72,110 | +3199 | 7.826 | 7.111 | +0.715 | 4474 |
| All NG28 baseline risk factors (UK cohort) | 47,125 | 42,578 | +4546 | 8.490 | 7.741 | +0.749 | 6069 |
FoH fear of hypoglycemia, GBP Great British pounds, HbA1c glycated hemoglobin, ICER incremental cost-effectiveness ratio, QALY quality-adjusted life year, rt-CGM real-time continuous glucose monitoring, SMBG self-monitoring of blood glucose